J. Stephenson

发表

Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans

Aaron Fenster, James Burke, Andrew R. Haas, 2011, Nature.

Effects of ketoconazole and esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumors

A. Tan, J. Botbyl, J. Stephenson, 2013, Cancer Chemotherapy and Pharmacology.

Abstract LB-121: Randomized phase II study of the efficacy and safety of gemcitabine + TH-302 (G+T) vs gemcitabine (G) alone in previously untreated patients with advanced pancreatic cancer

M. Borad, D. Ryan, S. Kroll, 2012 .

Randomized phase 2 study of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus erlotinib in patients with non-small cell lung cancer.

J. Nemunaitis, M. Edelman, J. Stephenson, 2014, Lung cancer.

Combined treatment of dendritoma vaccine and low-dose interleukin-2 in stage IV renal cell carcinoma patients induced clinical response: A pilot study.

T. Wagner, H. Bouton-Verville, J. Stephenson, 2007, Oncology reports.

A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer

M. Sherman, A. Hezel, A. El-Khoueiry, 2015, Clinical Cancer Research.

A phase Ib/II trial of AMG 655 and panitumumab (pmab) for the treatment (tx) of metastatic colorectal cancer (mCRC): Safety results.

P. Rougier, J. Infante, J. Stephenson, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety and efficacy of AMG 655 plus modified FOLFOX6 (mFOLFOX6) and bevacizumab (B) for the first-line treatment of patients (pts) with metastatic colorectal cancer (mCRC).

C. Fuchs, L. Saltz, F. Galimi, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase Ib study to evaluate the safety and efficacy of AMG 655 in combination with gemcitabine (G) in patients (pts) with metastatic pancreatic cancer (PC).

F. Civoli, J. Stephenson, H. Kindler, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The safety of IPI-926, a novel hedgehog pathway inhibitor, in combination with gemcitabine in patients (pts) with metastatic pancreatic cancer.

C. Fuchs, J. Hamm, B. Wolpin, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Complete remissions observed in acute myeloid leukemia following prolonged exposure to lintuzumab: a phase 1 trial

B. Wood, M. Maris, A. Raza, 2009, Leukemia & lymphoma.

An open-label, phase II study of the polo-like kinase-1 (Plk-1) inhibitor, BI 2536, in patients with relapsed small cell lung cancer (SCLC).

M. Socinski, Bruce E. Johnson, R. Govindan, 2017, Lung cancer.

An open-label clinical trial evaluating safety and pharmacokinetics of two dosing schedules of panitumumab in patients with solid tumors.

J. Crawford, H. Burris, R. Cohen, 2009, Clinical colorectal cancer.

A mechanistic proof-of-concept clinical trial with JX-594, a targeted multi-mechanistic oncolytic poxvirus, in patients with metastatic melanoma.

J. Diallo, A. Ribas, D. Kirn, 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

A Phase Ib multicenter, dose-escalation study of the polyamine analogue PG-11047 in combination with gemcitabine, docetaxel, bevacizumab, erlotinib, cisplatin, 5-fluorouracil, or sunitinib in patients with advanced solid tumors or lymphoma

David A. Smith, D. V. Von Hoff, L. Marton, 2020, Cancer Chemotherapy and Pharmacology.

An innovative, multi-arm, complete phase 1b study of the novel anti-cancer agent tasisulam in patients with advanced solid tumors

David A. Smith, D. V. Von Hoff, F. Braiteh, 2015, Investigational New Drugs.

A Phase I trial of the kinesin spindle protein (Eg5) inhibitor AZD4877 in patients with solid and lymphoid malignancies

G. Schwartz, D. Huszar, J. Stephenson, 2013, Investigational New Drugs.

Pharmacokinetic study of omacetaxine mepesuccinate administered subcutaneously to patients with advanced solid and hematologic tumors

J. Nemunaitis, M. Mita, A. Mita, 2012, Cancer Chemotherapy and Pharmacology.

A phase I trial of PX-12, a small-molecule inhibitor of thioredoxin-1, administered as a 72-hour infusion every 21 days in patients with advanced cancers refractory to standard therapy

G. Weiss, J. Stephenson, Julie C Martin, 2012, Investigational New Drugs.

A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer.

T. Mok, F. Kabbinavar, Y. Hei, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I trial of a murine antibody to MUC1 in patients with metastatic cancer: evidence for the activation of humoral and cellular antitumor immunity.

A. Tolcher, T. Whiteside, J. Stephenson, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancer.

N. Senzer, J. Nemunaitis, M. Morse, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Title The effect of different dosing regimens of motesanib on the gallbladder : a randomized phase 1 b study in patients with advanced solid tumors Permalink

L. Lipton, H. Hurwitz, L. Rosen, 2013 .

A randomized, double-blind, placebo-controlled study to evaluate the effect of repeated oral doses of pazopanib on cardiac conduction in patients with solid tumors

A. Tan, E. Heath, P. LoRusso, 2013, Cancer Chemotherapy and Pharmacology.

P3-138: A Phase I open label study of continuous oral treatment with BIBF 1120 together with carboplatin and paclitaxel treated patients with non–small cell lung cancer (NSCLC)

D. Camidge, D. Shapiro, J. Stephenson, 2007 .

Safety and pharmacokinetics (PK) of AMG 706 with panitumumab plus FOLFIRI or FOLFOX for the treatment of patients (pts) with metastatic colorectal cancer (mCRC)

H. Hurwitz, D. Goldstein, H. Burris, 2007 .

Dendritoma vaccination combined with low dose interleukin-2 in metastatic melanoma patients induced immunological and clinical responses.

T. Wagner, J. Stephenson, Jinhua Li, 2006, International journal of oncology.

Phase 2 trial of talabostat and cisplatin in patients with stage IV melanoma.

A. Pavlick, R. Gonzalez, S. O’Day, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Sequential ofatumumab and lenalidomide for the treatment of relapsed and refractory chronic lymphocytic leukemia and small lymphocytic lymphoma

J. Stephenson, R. Stuart, L. Afrin, 2015, Leukemia & lymphoma.

Phase 1 Study of Talabostat and Rituximab in Patients with Indolent Non-Hodgkin’s Lymphoma with Primary Resistance to or Progression Following Rituximab.

F. Giles, A. Al-Katib, J. Stephenson, 2004 .

Effects of Esomeprazole on the Pharmacokinetics of Lapatinib in Breast Cancer Patients

Sung-Bae Kim, Y. Im, L. Cartee, 2013, Clinical pharmacology in drug development.

Phase I multicenter study to assess the safety, tolerability, and pharmacokinetics of AZD4877 administered twice weekly in adult patients with advanced solid malignancies

G. Schwartz, A. Ho, L. Pace, 2008 .

Phase II study of synthadotin (SYN-D; ILX651) administered daily for 5 consecutive days once every 3 weeks (qdx5q3w) in patients (Pts) with inoperable locally advanced or metastatic melanoma

S. O’Day, E. Hersh, J. Stephenson, 2004 .

Phase II study of synthadotin (SYN-D; ILX651) administered daily for 5 consecutive days once every 3 weeks (qdx5q3w) in patients (Pts) with inoperable locally advanced or metastatic melanoma.

S. O’Day, E. Hersh, J. Stephenson, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract #LB-259: A pilot study utilizing molecular profiling of patients\#8217; tumors to find potential targets and select treatments for their refractory cancers

M. Bittner, R. Penny, D. Mallery, 2009 .

Phase I multicenter trial of perifosine in combination with sorafenib for patients with advanced cancers including renal cell carcinoma

R. Figlin, I. Henderson, J. Stephenson, 2008 .

Perifosine (P), active as a single agent for renal cell carcinoma (RCC), now in phase I trials combined with tyrosine kinase inhibitors (TKI)

I. Henderson, J. Stephenson, L. Campos, 2007 .

Phase I study of the specific endothelin A receptor antagonist zibotentan (ZD4054) combined with docetaxel in patients with metastatic castration-resistant prostate cancer: Assessment of efficacy, pain, and safety.

H. Burris, D. Trump, H. Payne, 2010 .

Preliminary study of the specific endothelin a receptor antagonist zibotentan in combination with docetaxel in patients with metastatic castration‐resistant prostate cancer

K. Miller, H. Burris, D. Trump, 2011, The Prostate.

Androgen Receptor Modulation Optimized for Response (ARMOR) Phase I and II Studies: Galeterone for the Treatment of Castration-Resistant Prostate Cancer

N. Vogelzang, W. Edenfield, M. Eisenberger, 2015, Clinical Cancer Research.

Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers.

Michael Bittner, David Mallery, David M Loesch, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I/II Trial of Custirsen (OGX-011), an Inhibitor of Clusterin, in Combination with a Gemcitabine and Platinum Regimen in Patients with Previously Untreated Advanced Non-small Cell Lung Cancer

M. Gleave, J. Nemunaitis, G. Nicholas, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A phase I trial of pan-Bcl-2 antagonist obatoclax administered as a 3-h or a 24-h infusion in combination with carboplatin and etoposide in patients with extensive-stage small cell lung cancer

R. Salgia, J. Stephenson, A. Chiappori, 2012, British Journal of Cancer.

A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer.

M. Meng, D. Lamm, J. Nemunaitis, 2012, The Journal of urology.

Randomized Phase Ib/II Trial of Rilotumumab or Ganitumab with Panitumumab versus Panitumumab Alone in Patients with Wild-type KRAS Metastatic Colorectal Cancer

E. Van Cutsem, J. Tabernero, N. Tebbutt, 2014, Clinical Cancer Research.

Abstract CT-07: ARMOR1: Safety of galeterone (TOK-001) in a Phase 1 clinical trial in chemotherapy naïve patients with castration resistant prostate cancer (CRPC)

N. Vogelzang, M. Taplin, J. Stephenson, 2012 .

Safety and Pharmacokinetics of Motesanib in Combination with Panitumumab and Gemcitabine-Cisplatin in Patients with Advanced Cancer

H. Burris, G. Otterson, Yu‐Nien Sun, 2011, Journal of oncology.

Phase Ib Study of Combination Therapy with MEK Inhibitor Binimetinib and Phosphatidylinositol 3‐Kinase Inhibitor Buparlisib in Patients with Advanced Solid Tumors with RAS/RAF Alterations

A. Bardia, Michael Thomas, P. LoRusso, 2019, The oncologist.

A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours

R. Berger, J. Edenfield, W. Dalton, 2014, British Journal of Cancer.

Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial—ECOG-ACRIN EA6134

J. Wolchok, M. Atkins, J. Sosman, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase 1‐2 study of imexon plus dacarbazine in patients with unresectable metastatic melanoma

A. Ribas, R. Gonzalez, S. O’Day, 2010, Cancer.

First-in-Human Study of AMG 820, a Monoclonal Anti-Colony-Stimulating Factor 1 Receptor Antibody, in Patients with Advanced Solid Tumors

A. Tolcher, E. Rasmussen, K. Papadopoulos, 2017, Clinical Cancer Research.

First-inHuman Study of AMG 820 , a Monoclonal Anti-Colony-Stimulating Factor 1 Receptor Antibody , in Patients with Advanced Solid Tumors

A. Tolcher, E. Rasmussen, K. Papadopoulos, 2017 .

Safety and pharmacokinetics (PK) of AMG 706 in combination with panitumumab and gemcitabine-cisplatin in patients (pts) with advanced cancer

J. Crawford, H. Burris, G. Otterson, 2007 .

MG98, a Second-Generation DNMT1 Inhibitor, in the Treatment of Advanced Renal Cell Carcinoma

K. Bélanger, J. Nemunaitis, R. Amato, 2012, Cancer investigation.

A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer.

C. Fuchs, H. Safran, F. Galimi, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase 1 study of PSMA ADC, an antibody‐drug conjugate targeting prostate‐specific membrane antigen, in chemotherapy‐refractory prostate cancer

P. Kantoff, N. Stambler, D. Petrylak, 2019, The Prostate.

Phase II assessment of talabostat and cisplatin in second-line stage IV melanoma

N. Senzer, J. Nemunaitis, A. Pavlick, 2009, BMC Cancer.

High‐Dose Taxol, Cyclophosphamide, and Cisplatin with Stem Cell Support in the Treatment of Metastatic Breast Cancer

J. Stephenson, S. Vukelja, M. Atkins, 1998 .

An open label phase II trial of the Plk1 inhibitor BI 2536, in patients with sensitive relapse small cell lung cancer (SCLC).

M. Socinski, R. Govindan, B. Johnson, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Motesanib with or without panitumumab plus FOLFIRI or FOLFOX for the treatment of metastatic colorectal cancer

H. Hurwitz, D. Goldstein, H. Burris, 2015, Cancer Chemotherapy and Pharmacology.

Phase 1 dose‐escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma

B. Rini, J. Stephenson, D. Healey, 2011, Cancer.

MG 98 , a Second-Generation DNMT 1 Inhibitor , in the Treatment of Advanced Renal Cell Carcinoma

K. Bélanger, J. Nemunaitis, R. Amato, 2012 .

Effects of low-fat and high-fat meals on steady-state pharmacokinetics of lapatinib in patients with advanced solid tumours

J. Schellens, A. Robidoux, L. Cartee, 2014, Investigational New Drugs.

A phase I study of the chinese herbal medicine PHY906 as a modulator of irinotecan-based chemotherapy in patients with advanced colorectal cancer.

Mark O'Rourke, Joe Stephenson, Edward Chu, 2011, Clinical colorectal cancer.

Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer.

M. Borad, D. Ryan, S. Kroll, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II open-label trial of bortezomib in patients with multiple myeloma who have undergone an autologous peripheral blood stem cell transplant and failed to achieve a complete response

R. Beveridge, J. Stephenson, R. Rifkin, 2012, Investigational New Drugs.

A placebo-controlled, randomized phase II study of conatumumab (C) or AMG 479 (A) or placebo (P) plus gemcitabine (G) in patients (pts) with metastatic pancreatic cancer (mPC).

C. Fuchs, H. Safran, E. Feigal, 2010 .

A phase I extension study of BBI608, a first-in-class cancer stem cell (CSC) inhibitor, in patients with advanced solid tumors.

J. Supko, D. Jonker, W. Edenfield, 2014 .

A phase Ib trial of IPI-926, a hedgehog pathway inhibitor, plus gemcitabine in patients with metastatic pancreatic cancer.

C. Fuchs, J. Hamm, B. Wolpin, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prostate-specific membrane antigen antibody drug conjugate (PSMA ADC): A phase I trial in metastatic castration-resistant prostate cancer (mCRPC) previously treated with a taxane.

P. Kantoff, N. Stambler, N. Vogelzang, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I clinical trial of galeterone (TOK-001), a multifunctional antiandrogen and CYP17 inhibitor in castration resistant prostate cancer (CRPC).

N. Vogelzang, M. Eisenberger, M. Taplin, 2012 .

A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer.

C. Fuchs, H. Safran, F. Galimi, 2012 .

Phase Ib/II study of cancer stem cell (CSC) inhibitor BBI608 combined with paclitaxel in advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma.

H. Lenz, T. Bekaii-Saab, S. Mikhail, 2015 .

Phase I Clinical Study of Seneca Valley Virus (SVV-001), a Replication-Competent Picornavirus, in Advanced Solid Tumors with Neuroendocrine Features

C. Rudin, N. Senzer, K. Burroughs, 2011, Clinical Cancer Research.

Abstract 2242: A randomized phase 2 study of the cyclin-dependent kinase (CDK) inhibitor Dinaciclib (SCH 727965) in patients with non-small cell lung cancer (NSCLC)

J. Nemunaitis, M. Edelman, J. Stephenson, 2011 .

Phase 2 study of talabostat and cisplatin in stage IV melanoma

A. Pavlick, J. Stephenson, C. Cunningham, 2005 .

PD3-3-7: Safety and Pharmacokinetics (PK) of AMG 706 With Carboplatin/Paclitaxel (C/P) and/or Panitumumab for the treatment of patients with advanced non-small cell lung cancer (NSCLC)

Yu‐Nien Sun, J. Stephenson, A. Sandler, 2007 .

Safety and pharmacokinetics (PK) of AMG 706, panitumumab, and gemcitabine/cisplatin (GC) for the treatment of advanced solid malignancies.

J. Crawford, J. Gilbert, J. Stephenson, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized, open-label phase II study of motesanib or bevacizumab in combination with paclitaxel and carboplatin (P/C) for advanced nonsquamous non-small cell lung cancer (NSCLC).

T. Mok, F. Kabbinavar, R. Sikorski, 2010 .

Optimizing obatoclax administration schedule: Safety and efficacy of 3-hour versus 24-hour infusion in combination with carboplatin and etoposide for patients with extensive-stage small cell lung cancer (ES-SCLC).

R. Salgia, J. Stephenson, A. Chiappori, 2010 .

A phase Ib trial of Bcl-2 inhibitor obatoclax in combination with carboplatin and etoposide for previously untreated patients with extensive-stage small cell lung cancer (ES-SCLC).

R. Salgia, J. Stephenson, A. Chiappori, 2009, Journal of Clinical Oncology.

Pharmacokinetic (PK) analysis of a phase I study of continuous oral treatment with the angiokinase inhibitor BIBF 1120, in combination with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer (NSCLC)

D. Camidge, J. Stephenson, P. Stopfer, 2008 .

Multi-Center Phase II Study of Perifosine (KRX-0401) Alone and in Combination with Dexamethasone (dex) for Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Promising Activity as Combination Therapy with Manageable Toxicity.

A. Jakubowiak, S. Lonial, Jeffrey N. Martin, 2007 .

Phase Ib of anticancer stem cell antibody OMP-59R5 (anti-Notch2/3) in combination with nab-paclitaxel and gemcitabine (Nab-P+Gem) in patients (pts) with untreated metastatic pancreatic cancer (mPC).

L. Smith, J. Bendell, J. Dupont, 2014 .

A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer

M. Sherman, A. Hezel, A. El-Khoueiry, 2015, Clinical Cancer Research.

Phase 1 dose‐escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma

B. Rini, J. Stephenson, D. Healey, 2011, Cancer.

Phase I/II Trial of Custirsen (OGX-011), an Inhibitor of Clusterin, in Combination with a Gemcitabine and Platinum Regimen in Patients with Previously Untreated Advanced Non-small Cell Lung Cancer

M. Gleave, J. Nemunaitis, G. Nicholas, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A phase I/II study of OGX-011 and a gemcitabine (GEM)/platinum regimen as first-line therapy in 85 patients with advanced non-small cell lung cancer

C. Canil, M. Vincent, J. Stephenson, 2007 .

The effect of motesanib treatment on the gallbladder: A randomized phase Ib study in patients (pts) with advanced solid tumors.

L. Lipton, H. Hurwitz, L. Rosen, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I Clinical Study of Seneca Valley Virus (SVV-001), a Replication-Competent Picornavirus, in Advanced Solid Tumors with Neuroendocrine Features

C. Rudin, N. Senzer, K. Burroughs, 2011, Clinical Cancer Research.

A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer.

Y. Hei, E. Feigal, J. Stephenson, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancer.

N. Senzer, M. Morse, J. Stephenson, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized Phase Ib/II Trial of Rilotumumab or Ganitumab with Panitumumab versus Panitumumab Alone in Patients with Wild-type KRAS Metastatic Colorectal Cancer

E. Van Cutsem, J. Tabernero, N. Tebbutt, 2014, Clinical Cancer Research.

P PROGNOSIS IMPACT OF POSTOPERATIVE RADIATION IN PATIENTS WITH RADICAL ESOPHAGECTOMY AND PATHOLOGIC LYMPH NODES POSITIVE ESOPHAGEAL CANCER

J. Reis-Filho, M. Borad, D. Ryan, 2012 .

Abstract CT137: First-in-human study of AMG 820, a monoclonal anti-CSF-1R (c-fms) antibody, in patients (pts) with advanced solid tumors

E. Rasmussen, K. Papadopoulos, J. Stephenson, 2016 .

A phase 1b study of the cancer stem cell inhibitor BBI608 administered with paclitaxel in patients with advanced malignancies.

W. Edenfield, C. Li, Wei Li, 2014 .